WO1992012714A1 - Food supplement - Google Patents
Food supplementInfo
- Publication number
- WO1992012714A1 WO1992012714A1 PCT/NL1992/000015 NL9200015W WO9212714A1 WO 1992012714 A1 WO1992012714 A1 WO 1992012714A1 NL 9200015 W NL9200015 W NL 9200015W WO 9212714 A1 WO9212714 A1 WO 9212714A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- food supplement
- supplement according
- hydroxyapatite
- food
- terised
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 24
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 5
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 5
- 239000011718 vitamin C Substances 0.000 claims abstract description 5
- 150000003700 vitamin C derivatives Chemical class 0.000 claims abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- RSYSVNVHLXTDIR-ZZMNMWMASA-L (2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2H-furan-4-olate;manganese(2+) Chemical compound [Mn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] RSYSVNVHLXTDIR-ZZMNMWMASA-L 0.000 claims description 2
- 229940008219 BORON CITRATE Drugs 0.000 claims description 2
- KUDUMIJONPZUKY-UHFFFAOYSA-K C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[B+3] Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[B+3] KUDUMIJONPZUKY-UHFFFAOYSA-K 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 229960003067 Cystine Drugs 0.000 claims description 2
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Iron(II) fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229960002429 Proline Drugs 0.000 claims description 2
- 229960003080 Taurine Drugs 0.000 claims description 2
- 229940011671 Vitamin B6 Drugs 0.000 claims description 2
- 229930003629 Vitamin B6 Natural products 0.000 claims description 2
- 229960003487 Xylose Drugs 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 229930003935 flavonoids Natural products 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 150000003697 vitamin B6 derivatives Chemical class 0.000 claims description 2
- SBCMUHSRBJVMOA-RXSVEWSESA-N (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one;magnesium Chemical compound [Mg].OC[C@H](O)[C@H]1OC(=O)C(O)=C1O SBCMUHSRBJVMOA-RXSVEWSESA-N 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 claims 1
- WWRJFSIRMWUMAE-ZZMNMWMASA-L zinc;(2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2H-furan-4-olate Chemical compound [Zn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] WWRJFSIRMWUMAE-ZZMNMWMASA-L 0.000 claims 1
- 206010073767 Developmental hip dysplasia Diseases 0.000 abstract description 2
- 241000282414 Homo sapiens Species 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 150000001639 boron compounds Chemical class 0.000 abstract 1
- 210000000988 Bone and Bones Anatomy 0.000 description 9
- 210000000845 Cartilage Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229960005069 Calcium Drugs 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229960004494 Calcium Gluconate Drugs 0.000 description 2
- NEEHYRZPVYRGPP-IYEMJOQQSA-L Calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N Glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical class CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N Itaconic acid Chemical class OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical class OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UKNAYQWNMMGCNX-UHFFFAOYSA-N sodium;[hydroxy(phenyl)methyl]-oxido-oxophosphanium Chemical compound [Na+].[O-][P+](=O)C(O)C1=CC=CC=C1 UKNAYQWNMMGCNX-UHFFFAOYSA-N 0.000 description 1
- 239000001384 succinic acid Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Definitions
- the invention relates to a food supplement, in ⁇ particular &n food supplement for the regeneration of bone 5 and cartilage in mammals.
- a food supplement according to the present invention provides a substantial improvement in comparison with the best result stated hitherto, as a growth and regeneration of bone and cartilage of at least
- the present invention relates essentially to a food supplement having as most important active component hydroxyapatite, preferably microcrystalline, as well as addition a substantial quantity of vitamin C, suitably in a 25 ratio of 10:1 to 1:10, preferably in a ratio of 5:1 tot 1:5 and most preferably in a ration of 3:1 to 1:3.
- Such prepa ⁇ rations will provide a growth and regeneration of bone and cartilage of at least 8% with suitable dosage over a suitable period of time under conditions which correspond 30 with those, used for determining the growth and regene ⁇ ration of bone and cartilage for calcium gluconate and hydroxyapatite as such.
- hydroxyapatite was used previously in - combination with amino acids, mucopolysaccharides, mag- 35 nesium, zinc, silica, manganese and some trace minerals, as well as calcium in bonded form.
- the hydroxyapatite is used in the preparation according to the present invention either as such or in a similar combination as the known preparation.
- the presence of a substantial amount of vitamin C causes a substantial improvement of the action on increase of bone and increase of cartilage in comparison with the action of the microcrystalline hydroxyapatite as such.
- the result thus obtained according to the invention may be improved still further by adding salts of hydroxy- carboxylic acids, in particular hydroxypolycarbox lic acids or polycarboxylic acids.
- suitable salts that may be incorporated in the preparation according to the invention are mentioned by way of example the sodium, potassium, calcium, magnesium, boron and aluminium salts of lactic acid, tartaric acid, pyruvic acid, citric acid, itaconic acid, oxalic acid, malonic acid, succinic acid and glutaric acid.
- suitable salts should not be considered as exhaustive.
- boron citrate is preferred.
- the salts mentioned above will provide the desired improvement by adding them in an amount of 0.5 to 5 % by weight, on the basis of the weight of the hydroxyapatite present.
- the preparation according to the present invention may contain minor amounts of potassium, calcium, magnesium, zinc of manganese ascorbate, calcium panthotenate, calcium phos ⁇ phate, magnesium sulfate hydrate, flavonoids, silica (preferably of organic origin), vitamin B6, iron fumarate, xylose and various amino acids, such as proline, lysine, cystine and taurine.
- the various components of the preparation according to the invention are preferably administered in a tablet, capsule or powder, as considered desirable, it will be obvious to the expert in the art, the optionally the various components, or if the circumstances demand, may be divided over two or more separate dosage units, each one comprising at least one component of the preparation according to the invention.
- the preparation according to the invention is especially suitable for improvement of the stability of a joint, the mobility of a joint and the power in mammals, including human beings, having the relevant problems. Bij way of example an improvement will be ob ⁇ tained thereby of the charging capacity of the hind legs in the case of hip dysplasia.
Abstract
A food supplement on the basis of an effective combination of hydroxyapatite and vitamin C for veterinary and also human application. It may contain optionally also a salt, a boron compound and/or various other additives, known as such. The hydroxyapatite should be microcrystalline for optimal results. The food supplement is especially effective in alleviating hip dysplasia.
Description
Food supplement.
The invention relates to a food supplement, in ^ particular &n food supplement for the regeneration of bone 5 and cartilage in mammals.
Food supplements obtainable hitherto for providing nutritious matter for bone generation, though providing some bone improvement, have been found substantially less active m comparison with the food supplements according to
10 the present invention. Thus it is declared, that under otherwise identical conditions calcium gluconate provides a growth and regeneration of bone and cartilage of 1.5%, while a food supplement with predominantly microcrystalline hydroxyapatite provides a growth and regeneration of bone
15 and cartilage of 6.1%. A food supplement according to the present invention provides a substantial improvement in comparison with the best result stated hitherto, as a growth and regeneration of bone and cartilage of at least
8% is obtained therwith under otherwise identical con-
20 ditions.
The present invention relates essentially to a food supplement having as most important active component hydroxyapatite, preferably microcrystalline, as well as addition a substantial quantity of vitamin C, suitably in a 25 ratio of 10:1 to 1:10, preferably in a ratio of 5:1 tot 1:5 and most preferably in a ration of 3:1 to 1:3. Such prepa¬ rations will provide a growth and regeneration of bone and cartilage of at least 8% with suitable dosage over a suitable period of time under conditions which correspond 30 with those, used for determining the growth and regene¬ ration of bone and cartilage for calcium gluconate and hydroxyapatite as such. It should be observed in this connection, that the hydroxyapatite was used previously in - combination with amino acids, mucopolysaccharides, mag- 35 nesium, zinc, silica, manganese and some trace minerals, as well as calcium in bonded form. The hydroxyapatite is used in the preparation according to the present invention either as such or in a similar combination as the known
preparation. The presence of a substantial amount of vitamin C causes a substantial improvement of the action on increase of bone and increase of cartilage in comparison with the action of the microcrystalline hydroxyapatite as such. The result thus obtained according to the invention may be improved still further by adding salts of hydroxy- carboxylic acids, in particular hydroxypolycarbox lic acids or polycarboxylic acids. As examples of suitable salts, that may be incorporated in the preparation according to the invention are mentioned by way of example the sodium, potassium, calcium, magnesium, boron and aluminium salts of lactic acid, tartaric acid, pyruvic acid, citric acid, itaconic acid, oxalic acid, malonic acid, succinic acid and glutaric acid. The above enumeration of suitable salts should not be considered as exhaustive. On the basis of the present experience boron citrate is preferred. The salts mentioned above will provide the desired improvement by adding them in an amount of 0.5 to 5 % by weight, on the basis of the weight of the hydroxyapatite present. Apart from the components as mentioned above, the preparation according to the present invention may contain minor amounts of potassium, calcium, magnesium, zinc of manganese ascorbate, calcium panthotenate, calcium phos¬ phate, magnesium sulfate hydrate, flavonoids, silica (preferably of organic origin), vitamin B6, iron fumarate, xylose and various amino acids, such as proline, lysine, cystine and taurine.
Though the various components of the preparation according to the invention are preferably administered in a tablet, capsule or powder, as considered desirable, it will be obvious to the expert in the art, the optionally the various components, or if the circumstances demand, may be divided over two or more separate dosage units, each one comprising at least one component of the preparation according to the invention. The preparation according to the invention is especially suitable for improvement of the stability of a joint, the mobility of a joint and the power in mammals, including human beings, having the relevant
problems. Bij way of example an improvement will be ob¬ tained thereby of the charging capacity of the hind legs in the case of hip dysplasia. As dosing usually 30-100 mg/kg body weight/day, divided over 3 dosages per day, will be administered over a period of at least 1 month, preferably for at least 3 monts, and if desired so much longer as the circumstances may require. Thus 3 (three) lame dogs, which had been treated for 3 months in the manner as described above, could walk and jump again undisturbed at the end of said period.
It will be obvious to the expert in the art to make modifications or changes within the framework of what has been described above, without deviating from the inventive concept.
Claims
1. A food supplement, characterised in that it comprises an effective combination of at least hydroxy- apatite and vitamin C.
2. A food supplement according to claim 1, charac¬ terised in that the hydroxyapatite is microcrystalline.
3. A food supplement according to claim 1 or 2, characterised in that it comprises hydroxyapatite and vitamin C in a ratio of 10:1 to 1:10.
4. A food supplement according to claim 3, charac- terised in that the ratio is from 5:1 to 1:5.
5. A food supplement according to claim 4, charac¬ terised in that the ratio is from 3:1 to 1:3.
6. A food supplement according to one or more of the preceding claims, characterised in that it comprises in addition a salt of a hydroxycarboxylic acid, a poly- σarboxylic acid or a hydroxypolyσarboxylic acid.
7. A food supplement according to claim 6, charac¬ terised in that it comprises boron citrate.
8. A food supplement according to claim 6 or 7, characterised in that it comprises the salt in an amount of 0.5 to 5 % by weight, on the basis of the weight of the hydroxyapatite present.
9. A food supplement according to one or more of the preceding claims, characterised in that it comprises in minor amounts one or more of the following components: potassium, calcium, magnesium, zinc and manganese ascor- bate, calcium panthotenate, calcium phosphate, magnesium sulfate hydrate, flavonoids, silica, vitamin B6, iron
fumarate, xylose and various amino acids, such as proline, lysine, cystine and taurine.
10. Application of a food supplement according to one or more of the preceding claims, characterised in that it is administered in the form of a tablet.
11. Application of a food 'supplement according to one or more of the preceding claims, characterised in that it is administered in the form of a capsule.
12. Application of a food supplement according to claim 10 or 11, characterised in that it is administered in an amount of 30/100 mg/kg body weight/day.
13. Application of a food supplement according to one or more of the claims 10-12, characterised in that the food supplement is subdivided in separate entities, each one comprising at least one main component.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9100105A NL9100105A (en) | 1991-01-23 | 1991-01-23 | FOOD SUPPLEMENT. |
| NL9100105 | 1991-01-23 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1992012714A2 WO1992012714A2 (en) | 1992-08-06 |
| WO1992012714A1 true WO1992012714A1 (en) | 1992-08-06 |
| WO1992012714A3 WO1992012714A3 (en) | 1992-10-15 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5459162A (en) | Method and composition for improving the weight gain of poultry | |
| JPS62236448A (en) | Method for feeding ketoisocaproate to chicken for producing egg | |
| GB2142031A (en) | A process for the preparation of protein concentrate from blood | |
| US5824707A (en) | Method for improving the weight gain and feed conversion efficiency of swine | |
| KR100505971B1 (en) | A pig feed compositions | |
| Leibholz | Arginine requirements of pigs between 7 and 28 days of age | |
| US4760090A (en) | Method of feeding ketoisocaproate to cattle and sheep | |
| NZ201487A (en) | Fodder or fodder additive containing watersoluble titanium complex | |
| WO1992012714A1 (en) | Food supplement | |
| EP0093123B1 (en) | Process for the preparation of a composition suitable for promoting the utilization (digestibility) of fodder by the animals | |
| KR100394034B1 (en) | Compositions containing easily absorbable calcium and methods for preparing the same | |
| WO1992012714A2 (en) | Food supplement | |
| CA2359874A1 (en) | Method for reducing hip joint laxity | |
| WO2001091577A1 (en) | Solid feed and method for preventing bovine hoof disease | |
| HUT56500A (en) | Process for facilitate development of swine | |
| Maddy et al. | Growth and metabolism studies with rats fed rations containing purified amino acids | |
| CA2361542A1 (en) | Chromium-carboxylic acid feed supplement | |
| GB2153670A (en) | A stable pharmaceutical composition for treating ketosis containing propylene glycol | |
| CA2106274C (en) | Carnitine-supplemented diet for starter pigs | |
| CS256362B2 (en) | Method of ruminants feeding | |
| JPH0335896B2 (en) | ||
| EP2408317A1 (en) | Dietary supplement | |
| JPH04166039A (en) | Pet food | |
| JP7432255B1 (en) | Pharmaceutical composition for oral administration | |
| RU2006123220A (en) | FOOD AND FEED ADDITIVE AND ITS APPLICATION |